Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated: April 20, 2026

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 246    

Filtered results: 246

Mineralocorticoid Receptor Antagonists: Efficacy and Safety in Chronic Kidney Disease

Mottl A. et al, DOM. 2026

Mottl A, 25 03 2026

Finerenone in Type 1 Diabetes and Chronic Kidney Disease

Heerspink H., et al., NEJM. 2026

Heerspink H, 20 03 2026

Utilization and Clinical Characteristics of Patients with Type 2 Diabetes and Chronic Kidney Disease Prescribed Finerenone in the United States

Kovesdy C., et al., JCTE. 2026

Kovesdy C, 20 03 2026

Finerenone Utilization for Chronic Kidney Disease and Diabetes: Multicenter Real-World Study in the United States

Lin W., et al, JACC. 2026

Lin W, 18 03 2026

Sex Differences in Cardiovascular–Kidney–Metabolic Syndrome: The FINE-HEART Pooled Analysis

Pablon M., et al, EHJ. 2026

Pabon M, 11 03 2026

Clinical Risk Prediction Models for Worsening Heart Failure Events and All-Cause Mortality in Adults with Mild-to-Moderate Chronic Kidney Disease

Patel S., et al., ESC-HF. 2026

Patel S, 20 02 2026

The Urinary Albumin‐to‐Creatinine Ratio Can Direct Personalized Prevention and Treatment for Cardiovascular and Chronic Kidney Disease

Kramer H., et al, JIM. 2026

Kramer H, 20 02 2026

Diabetic kidney disease, biomarkers, and finerenone

Verma A., et al, DOM. 2026

Verma A, 15 01 2026

Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY

Weingold R., et al, JDC. 2026

Weingold R, 15 01 2026

Baseline kidney function, albuminuria, and urine albumin-creatinine ratio reduction with finerenone, empagliflozin, or both Post hoc analyses of the CONFIDENCE trial

Mottl A., et al, JASN. 2025

Mottl A, 09 12 2025